This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Pulmonary Diseases, Other  • Oncology  • Alert me on articles by topic

Amr Hanbali, MD; Khaled Al-Khasawneh, MD; Christine Cole-Johnson, PhD; George Divine, PhD; Haytham Ali, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cancer can spread by both lymphatic and hematogenous routes, and metastases are found most commonly in organs fed by the downstream lymphatic and blood flow.¹ The tumor cells secrete proteinases or induce proteinase secretion by stromal cells that lead to degradation of the architecture of vascular basal membranes, creating local access through which to migrate into vasculature. In patients with long-standing diabetes mellitus, diabetic microangiopathy renders the vascular basal membrane less digestible by tumor cells, which may play a role in impeding neoplastic cell spread and metastasis.^2-3 There has been debate in the literature concerning the protective effect of diabetes on patients with cancer in terms of improving their mortality. In reference to the 2 letters published in the ARCHIVES,^4-5 we undertook a larger database review to investigate the possible hypothesis that diabetes . . . [Full Text of this Article]

AUTHOR INFORMATION